Drug Development Costs Criticized

The journal BioSocieties has published a study critical of the cost estimates of new drug development used by PhRMA and Tufts CSDD. The article notes that PhRMA and Tufts claim costs 18 times higher than those analyzed and verified by the authors: $43.4 million versus PhRMA and Tufts’ $802 million ($1.3 billion in 2011). Who’s right? And what’s missing from these numbers?  Continue reading at ComplianceZen.com →